Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05627310
Other study ID # AIAD202204
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 1, 2022
Est. completion date March 31, 2024

Study information

Verified date November 2022
Source Eye & ENT Hospital of Fudan University
Contact Yu-Xuan Shi, MD PhD
Phone +8618952373378
Email syxent@hotmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Develop a deep learning algorithm via nasal endoscopic images from eight NPC treatment centerto detect and screen nasopharyngeal carcinoma(NPC).


Description:

Nasopharyngeal carcinoma (NPC) is an epithelial cancer derived from nasopharyngeal mucosa. Nasal endoscopy is the conventional examination for NPC screening. It is a major challenge for inexperienced endoscopists to accurately distinguish NPC and other benign dieseases. In this study, we collcet multi-center endoscopic images and train a deep learning model to detect NPC and indicate tumor location. Then, the model perfomance will be compared with endoscopists and be tested prospectively with external dataset.


Recruitment information / eligibility

Status Recruiting
Enrollment 50000
Est. completion date March 31, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - The quality of endoscopic images should clinical acceptable. - Patients were diagnosed with biopsy(NPC, benign hyperplasia). Control corhort(normal nasopharynx) don't require bispsy result. Exclusion Criteria: - images with spots from lens flares or stains, and overexposure were excluded from further analysis. - image can not expose most part of lesion clearly.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Diagnostic
Training dataset was used to train the deep learning model, which was validated and tested by external dataset.

Locations

Country Name City State
China Xiangya Hospital of Central South University Changsha Hunan
China Fujian Medical University Union Hospital Fuzhou Fujian
China The People' s Hospital of Jiangmen Jiangmen Guangdong
China The First Affiliated Hospital of Nanchang University Nanchang Jiangxi
China First Affiliated Hospital of Guangxi Medical University Nanning Guangxi
China The People' s Hospital of Guangxi Zhuang Autonomous Region Nanning Guangxi
China Quan Zhou First Affiliated Hospital of Fujian Medical University Quanzhou Fujian
China Eye&ENT Hospital of Fudan University Shanghai Shanghai

Sponsors (8)

Lead Sponsor Collaborator
Eye & ENT Hospital of Fudan University First Affiliated Hospital of Guangxi Medical University, Fujian Medical University Union Hospital, Quan Zhou First Affiliated Hospital of Fujian Medical University, The First Affiliated Hospital of Nanchang University, The People' s Hospital of Guangxi Zhuang Autonomous Region, The People' s Hospital of Jiangmen, Xiangya Hospital of Central South University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area under the receiver operating characteristic curve of the deep learning algorithm The investigators will calculate the area under the receiver operating characteristic curve of deep learning algorithm and compare this index between deep learning system and human doctors. baseline
Secondary Sensitivity of the deep learning system The investigators will calculate the sensitivity of deep learning algorithm and compare this index between deep learning system and human doctors. baseline
Secondary Specificity of the deep learning system The investigators will calculate the specificity of deep learning algorithm and compare this index between deep learning system and human doctors. baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05979961 - Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT06055816 - Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma Phase 2
Recruiting NCT05547971 - Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics
Not yet recruiting NCT05020925 - SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 1/Phase 2
Not yet recruiting NCT04548271 - Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 2
Not yet recruiting NCT04547088 - Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 2
Recruiting NCT02795169 - Trail Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Terminated NCT02569788 - Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Terminated NCT02801487 - Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Completed NCT02237924 - Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma Phase 2
Recruiting NCT02044562 - Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients N/A
Terminated NCT01694576 - NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation Phase 2
Recruiting NCT01462903 - A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors Phase 1
Completed NCT01271439 - Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma Phase 2
Completed NCT00535795 - Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Phase 3
Completed NCT00379262 - Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma Phase 3
Completed NCT03398980 - Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy N/A
Completed NCT01309633 - Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC) Phase 2